Cancer Management and Research最新文献

{"title":"Synchronous Metastatic Esophageal Squamous Cell Carcinoma and Acute Myeloid Leukemia: A Case Report.","authors":"Youssef Abbas, Mohammad Alaa Aldakak, Hamza Hdeoa, Bassel Ibrahim, Younes Souleiman","doi":"10.2147/CMAR.S609006","DOIUrl":"10.2147/CMAR.S609006","url":null,"abstract":"<p><strong>Background: </strong>Synchronous presentation of solid and hematologic malignancies is uncommon, and coexistence of esophageal squamous cell carcinoma (ESCC) with acute myeloid leukemia (AML) at initial evaluation is exceptionally rare. Cytopenias may be misattributed to malnutrition, chronic disease, or the solid tumor itself.</p><p><strong>Case presentation: </strong>A 57-year-old Syrian man who was a heavy smoker presented with progressive dysphagia, profound weight loss, weakness, and pallor. Endoscopy revealed a circumferential obstructing esophageal lesion. Computed tomography demonstrated a distal esophageal mass extending to the gastric cardia, para-aortic lymphadenopathy, and multiple hepatic lesions radiologically consistent with metastases. Histopathology showed invasive high-grade carcinoma with pseudo-signet ring morphology; mucin staining was negative, and immunohistochemistry supported high-grade ESCC (p40 positive; CK7 and CEA negative). Laboratory testing revealed severe pancytopenia (white blood cell count approximately 0.6 × 10⁹/L, hemoglobin 6.9 g/dL, and platelets approximately 55 × 10⁹/L) with markedly elevated lactate dehydrogenase. Bone marrow evaluation and flow cytometry identified approximately 46% myeloid blasts expressing CD117, CD34, CD33, CD13, myeloperoxidase, HLA-DR, and dim CD25, with aberrant CD7 expression in 31% of cells, establishing the diagnosis of AML. A feeding jejunostomy was placed for nutritional support, and the patient was referred for multidisciplinary management.</p><p><strong>Case discussion: </strong>Severe or unexplained cytopenias in patients with esophageal malignancy warrant prompt hematologic evaluation, including bone marrow examination, to exclude a concomitant myeloid neoplasm and guide individualized treatment sequencing.</p><p><strong>Conclusion: </strong>Synchronous metastatic ESCC and AML require early multidisciplinary assessment to avoid diagnostic delay and optimize supportive and disease-directed care.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"18 ","pages":"609006"},"PeriodicalIF":2.6,"publicationDate":"2026-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13453384/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148700734","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Awareness and Dietary Practices Related to Fruit and Vegetable Consumption for Cancer Prevention in Mogadishu, Somalia: A Community-Based Cross-Sectional Study.","authors":"Ibrahim Abubakar Abdi, Mohamed Ismael Iman, Abdiweli Mohamed Abdi","doi":"10.2147/CMAR.S616632","DOIUrl":"10.2147/CMAR.S616632","url":null,"abstract":"<p><strong>Background: </strong>Fruit and vegetable consumption is an important component of healthy dietary practices and noncommunicable disease prevention. However, evidence on awareness, dietary practices, and access barriers related to fruit and vegetable consumption remains limited in Somalia. This study assessed awareness and self-reported dietary practices related to fruit and vegetable consumption for cancer prevention among adults in Mogadishu.</p><p><strong>Methods: </strong>A community-based cross-sectional study was conducted among 420 adults in Mogadishu, Somalia, from November 2025 to February 2026. Participants were selected using a multistage sampling approach across the 20 districts of Mogadishu. Data were collected through a structured interviewer-administered questionnaire covering sociodemographic characteristics, knowledge and attitudes, dietary practices, lifestyle factors, and accessibility barriers. Descriptive statistics and Pearson's chi-square tests were used to analyze the data, with statistical significance set at p<0.05.</p><p><strong>Results: </strong>The response rate was 99.5%. Overall, 71.4% of participants had heard that fruits and vegetables may help reduce cancer risk, and 85.0% agreed or strongly agreed that they are important for health. However, only 30.0% reported daily fruit intake, 40.0% reported daily vegetable intake, and 40.0% consumed only 0-1 serving per day. Limited access and food insecurity were reported by 40.0% and 45.0% of participants, respectively. Education level was significantly associated with cancer-prevention awareness (p<0.001), belief that low intake increases cancer risk (p=0.003), and attitudes toward fruit and vegetable importance (p<0.001). Access to fruits and vegetables and food insecurity were significantly associated with daily servings (both p<0.001).</p><p><strong>Conclusion: </strong>Awareness and positive attitudes were common, but self-reported intake remained below recommended levels. Findings suggest a knowledge-practice gap associated with socioeconomic and accessibility barriers.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"18 ","pages":"616632"},"PeriodicalIF":2.6,"publicationDate":"2026-08-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13450605/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148696965","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Astragalin Suppresses Colorectal Carcinogenesis by Targeting Proliferation, Oxidative Stress, and Inflammation.","authors":"Suhayla Hamad Shareef, Haween Toufiq Nanakaly, Salam Adil Ahmed, Noor Ali Gheni, Derin Nabaz Fisal, Nabaz Fisal Shakir Agha, Mahmood Ameen Abdulla","doi":"10.2147/CMAR.S578138","DOIUrl":"10.2147/CMAR.S578138","url":null,"abstract":"<p><strong>Background: </strong>Colorectal cancer (CRC) is a leading cause of cancer-related death worldwide. This study evaluated astragalin's (AST) anti-proliferative and chemopreventive effects on CRC.</p><p><strong>Methods: </strong>AST's effects were assessed in vitro on Caco-2 and HT-29 cells and in vivo on azoxymethane (AOM)-induced aberrant crypt foci (ACF) in rats. Rats received AST (50 or 100 mg/kg, 60 days) or 5-fluorouracil (5-FU) (35 mg/kg, 5 days).</p><p><strong>Results: </strong>AST inhibited Caco-2 and HT-29 cell growth (IC50: 20.15-34.50 µg/mL). In AOM-induced rats, AST reduced ACF formation, improved colon histology, downregulated β-catenin, and upregulated Bax. AST also enhanced superoxide dismutase (SOD) and catalase (CAT) activities, reduced malondialdehyde (MDA) levels, and modulated tumor necrosis factor alpha (TNF-α), interlukin-6 (IL-6), and IL-10 levels.</p><p><strong>Conclusion: </strong>AST demonstrated chemopreventive activity against CRC by exerting antiproliferative, antioxidant, and anti-inflammatory effects, supporting its potential as a therapeutic agent.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"18 ","pages":"578138"},"PeriodicalIF":2.6,"publicationDate":"2026-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13436567/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148673058","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Platform-Independent Binary Gene-Pair Signature Derived from CRPC-Enriched Single-Cell Transcriptomics for Predicting Recurrence-Free Survival in Prostate Cancer.","authors":"Yu He, Boyang Li, Zhaojie Tan, Kuanyao Jiang, Wenyue Ju, Weidong Yu, Meng Zhang, Chaozhao Liang","doi":"10.2147/CMAR.S623563","DOIUrl":"10.2147/CMAR.S623563","url":null,"abstract":"<p><strong>Background: </strong>Recurrence-free survival (RFS) following radical prostatectomy is a pivotal measure of therapeutic success in prostate cancer (PCa), yet conventional clinicopathological tools offer limited discriminative accuracy. We sought to construct a platform-independent prognostic signature to predict RFS by capturing early molecular traces of advanced disease potential.</p><p><strong>Methods: </strong>Single-cell RNA sequencing data were analyzed to identify malignant epithelial subclusters and evaluate their compositional changes during the transition to castration-resistant prostate cancer (CRPC). We benchmarked 12 machine learning algorithms and 104 algorithmic combinations to develop a robust binary gene-pair signature in TCGA-PRAD cohort (n = 493) and validated in five external cohorts (n = 694). Downstream analyses included functional enrichment, immune and mutational profiling, drug sensitivity prediction and virtual knockouts.</p><p><strong>Results: </strong>A 36-gene-pair signature was established, showing robust performance in predicting RFS across five external validation cohorts, with an average C-index of 0.725. Distinct signatures in signaling and metabolic processes were identified between the two risk groups through enrichment analysis. High-risk patients exhibited an immune-inflamed microenvironment with elevated <i>TP53</i> mutation frequency and greater tumor mutational burden, and shared significant transcriptional similarities with responders to anti-PD-1 immunotherapy. These immunotherapy-related findings are hypothesis-generating and require prospective validation. Virtual knockout identified <i>CKS2</i> as a risk-associated candidate gene linked to an androgen-responsive network, suggesting <i>CKS2</i>'s potential role in the molecular reprogramming associated with PCa progression.</p><p><strong>Conclusion: </strong>The 36-gene-pair binary signature provides robust RFS risk stratification. High-risk individuals exhibit transcriptional similarity to reported anti-PD-1 therapy responders, and <i>CKS2</i> emerges as a prognostic hub warranting validation.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"18 ","pages":"623563"},"PeriodicalIF":2.6,"publicationDate":"2026-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13436091/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148673074","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Novel Single-Stage Transcervical Submandibular Approach for a Giant Multicompartmental Pterygopalatine Fossa Schwannoma: A Case Report and Surgical Strategy.","authors":"Seyed Reza Mousavi, Majid Reza Farrokhi, Seyed Basir Hashemi, Niloofar Borzou, Gholamreza Motazedian, Keyvan Eghbal, Kamran Hosseini, Hesam Abdolhoseinpour, Saeed Tayebi Khorami","doi":"10.2147/CMAR.S620316","DOIUrl":"10.2147/CMAR.S620316","url":null,"abstract":"<p><strong>Background: </strong>Giant schwannomas originating in the pterygopalatine fossa (PPF) with multicompartmental extension pose a considerable surgical challenge.</p><p><strong>Case presentation: </strong>This report details the management of a 34-year-old female who presented with progressive facial numbness, dysphagia, and unilateral facial asymmetry secondary to a voluminous PPF schwannoma.</p><p><strong>Imaging findings: </strong>Preoperative imaging characterized a solid-cystic expansile mass with involvement of the maxillary sinus, infratemporal fossa, parapharyngeal space, and the anterolateral craniovertebral junction, including encasement of the internal carotid artery.</p><p><strong>Surgical approach: </strong>Given the tumor's significant lateral and posterior-inferior extension that precluded a purely endoscopic resection, a tailored transcervical submandibular approach was utilized. This open corridor provided direct lateral access, enabling safe proximal vascular control and permitting meticulous neurovascular dissection.</p><p><strong>Results: </strong>Gross-total resection was ultimately achieved without the need for mandibular osteotomy or transfacial incisions. The patient's postoperative course was uncomplicated, with preservation of neurological function, and follow-up imaging confirmed complete resection.</p><p><strong>Conclusion: </strong>This case highlights the novel single-stage transcervical submandibular approach as a viable and effective surgical strategy for select, extensive PPF schwannomas with dominant lateral and neurovascular involvement, serves as a critical alternative when endoscopic access is insufficient. To our knowledge, this is the first report of a single-stage transcervical submandibular resection for a multicompartmental PPF schwannoma with such extensive lateral and vascular involvement, unlike previous studies have described multi-staged procedures for similar complex lesions.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"18 ","pages":"620316"},"PeriodicalIF":2.6,"publicationDate":"2026-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13436082/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148673033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Cuproptosis-Associated AL139023.1/miR-139-5p/ELOVL5 ceRNA Axis Regulates Proliferation, Migration, and Cell Cycle in Esophageal Squamous Cell Carcinoma.","authors":"Kai Liang, Yun Gao, Xiangyu Zhang, Jin Yang","doi":"10.2147/CMAR.S592300","DOIUrl":"10.2147/CMAR.S592300","url":null,"abstract":"<p><strong>Purpose: </strong>To investigate the regulatory mechanism of cuproptosis-associated competing endogenous RNA (ceRNA) networks in esophageal squamous cell carcinoma (ESCC) and elucidate the role of the AL139023.1/miR-139-5p/ELOVL5 axis in ESCC progression.</p><p><strong>Patients and methods: </strong>Laboratory models of ESCC were used to quantify copper ions and reactive oxygen species (ROS) following ELOVL5 suppression. Functional assays assessed cell proliferation, cell cycle progression, and migration. Reporter gene assays evaluated ceRNA interactions between AL139023.1 and miR-139-5p, and rescue experiments validated the AL139023.1-ELOVL5 regulatory dependency.</p><p><strong>Results: </strong>Suppression of ELOVL5 triggered cuproptosis in ESCC cells. The AL139023.1/miR-139-5p/ELOVL5 axis modulated ESCC cell proliferation, cell cycle progression, and migration. AL139023.1 acted as a competing endogenous RNA that sponged miR-139-5p to upregulate ELOVL5 expression. The protumorigenic effects of AL139023.1 on ESCC malignant progression were partially dependent on ELOVL5.</p><p><strong>Conclusion: </strong>These findings reveal a novel cuproptosis-related ceRNA regulatory network in ESCC mediated by the AL139023.1/miR-139-5p/ELOVL5 axis, which holds promise as a diagnostic biomarker, a prognostic indicator, and a therapeutic target for ESCC, highlighting its clinical relevance.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"18 ","pages":"592300"},"PeriodicalIF":2.6,"publicationDate":"2026-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13390684/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148560653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pre-Infusion Host-Marrow Vulnerability in CD19- and BCMA-Directed CAR T-Cell Therapy: Clonal Hematopoiesis, Hematotoxicity, and Therapy-Related Myeloid Neoplasia.","authors":"Yong Liu, Guiyu Su, Ruijin Li, Shuang Wang","doi":"10.2147/CMAR.S629588","DOIUrl":"10.2147/CMAR.S629588","url":null,"abstract":"<p><p>CD19- and B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR T-cell) therapies have improved outcomes in relapsed or refractory B-cell lymphoid malignancies and multiple myeloma, but late hematologic complications are increasingly relevant as survivorship expands. This narrative review examines how pre-infusion clonal hematopoiesis (CH), clonal hematopoiesis of indeterminate potential (CHIP), clonal cytopenia of undetermined significance (CCUS), marrow reserve, prior genotoxic exposure, inflammatory stress, and disease-platform context shape the risks of prolonged cytopenia and therapy-related myeloid neoplasms (t-MN) after CAR T-cell therapy. Available evidence suggests that high-risk clonal architecture, particularly TP53-mutated or DNA damage response-associated clones, clonal cytopenia, larger or multiple clones, and heavy prior cytotoxic exposure, is more clinically informative than CHIP positivity alone. By contrast, associations between unstratified CH and prolonged cytopenia remain heterogeneous. CD19 lymphoma and BCMA myeloma settings share clonal-selection biology but differ in marrow ecology, treatment history, baseline cytopenia, inflammatory burden, and surveillance windows. For clinical translation, risk assessment should not rely on universal CHIP screening or binary genomic classification. Instead, clonal-risk models, hematotoxicity-risk models, baseline blood counts, inflammatory markers, prior therapy exposure, and disease-platform context should be integrated to identify patients who may benefit from intensified myeloid surveillance, supportive-care planning, and earlier marrow reassessment while preserving access to CAR T-cell therapy.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"18 ","pages":"629588"},"PeriodicalIF":2.6,"publicationDate":"2026-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13390675/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148560642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"<i>Piper nigrum</i> L. Extract Modulates Cell Cycle and Promotes Apoptosis-Like Cell Death in BT-474 Breast Cancer Cells with Similar Effects in MCF-7 Cells.","authors":"Hesti Lina Wiraswati, Julia Ramadhanti, Enny Rohmawaty, Afiat Berbudi, Wulan Mayasari, Amila Laelalugina, Ali Abdullah Afif, Audrey Madina Dewi Setiawan, Naila Fathiyah Mufarrihah Sofwah, Raina Athaayaa Edzana, Katarina Vučević, Nur Akmalia Hidayati, Keiichi Mochida, Ilma Fauziah Ma'ruf","doi":"10.2147/CMAR.S604276","DOIUrl":"10.2147/CMAR.S604276","url":null,"abstract":"<p><strong>Purpose: </strong>Cancer therapy remains challenging because of recurrence, drug resistance, and severe side effects, driving the search for novel complementary strategies. In this study, we explore, for the first time, the potential of <i>Piper nigrum</i> L. (<i>P. nigrum</i> L. black pepper), a widely used spice known for its bioactive properties, in treating BT-474 luminal B and MCF-7 luminal A breast cancer cells.</p><p><strong>Materials and methods: </strong>BT-474 cells were treated with <i>P. nigrum</i> L. ethanolic extract (PNEE). Cytotoxicity, cell morphology, gene and protein expression, cell death and cell cycle progression were evaluated using the MTT, microscopy, Reverse Transcriptase Quantitative Polymerase Chain Reaction (RT-qPCR), Enzyme-Linked Immunosorbent Assay (ELISA), and flow cytometry, respectively. MCF-7 cells were included as a comparative breast cancer model, whereas 3T3-L1 cells were used as a non-cancerous model.</p><p><strong>Results: </strong>Our findings demonstrate PNEE's multimodal activity in BT-474 cells, decreasing cell viability with an IC₅₀ of 58 ppm, and significantly suppressed colony formation. PNEE induced S-phase cell cycle arrest, and modulated several cancer-associated markers, including EGFR, PI3K/AKT pathway components, <i>cyclin A, MMP-9, HIF-1α</i>, and <i>BCL2</i>. Furthermore, PNEE elicited a regulated cell death phenotype with apoptotic features, distinct Annexin V/PI profiles in BT-474 luminal B and MCF-7 luminal A breast cancer cells. In addition, PNEE showed lower cytotoxicity toward non-cancerous 3T3-L1 cells under experimental condition tested.</p><p><strong>Conclusion: </strong>PNEE exerts multiple anticancer effects in BT-474 luminal B breast cancer cells and induces a regulated cell death phenotype that does not fully conform to a canonical caspase-dependent apoptotic pattern. Distinct cell death responses observed between BT-474 and MCF-7 cells further suggest that breast cancer subtype-specific factors may influence the cellular response to PNEE. These findings support further investigation of PNEE, including mechanistic studies and evaluation of efficacy and safety in appropriate in vivo models.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"18 ","pages":"604276"},"PeriodicalIF":2.6,"publicationDate":"2026-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13390677/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148560710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Targeted Immune Checkpoint Inhibitor Adjuvant Therapy on Recurrence-Free Survival and Functional Recovery in Stage III Tongue Cancer Patients: A Retrospective Cohort Study.","authors":"Chengjie Li, Jing Li, Yuyang Zhou, Jingjing Kong, Yi Shuai, Yanfeng Lou","doi":"10.2147/CMAR.S619697","DOIUrl":"10.2147/CMAR.S619697","url":null,"abstract":"<p><strong>Background: </strong>Stage III tongue cancer has a poor prognosis despite conventional adjuvant therapies. Immune checkpoint inhibitors show promise in oncology, but their impact on survival and functional outcomes in tongue cancer remains underexplored.</p><p><strong>Methods: </strong>This retrospective cohort study included 67 stage III tongue cancer patients, defined into a convention group (n=36) and a targeted immune checkpoint inhibitor (TICI) group (n=31). All received postoperative radiotherapy or chemoradiotherapy; the TICI group also received camrelizumab. Recurrence-free survival (RFS), swallowing function (EAT-10), speech function (RDA), and quality of life (UW-QOL) were assessed before treatment and at 1, 3, 6, and 12 months post-treatment.</p><p><strong>Results: </strong>The TICI group showed significantly prolonged RFS (P<0.001). Swallowing and speech function improved more rapidly and substantially in the TICI group at all post-treatment intervals (all P<0.05). Quality of life was also significantly higher in the TICI group throughout follow-up (all P<0.05). Multivariate analysis confirmed TICI as a protective factor for RFS (HR=0.689) and swallowing recovery (OR=0.612), while advanced T stage (T3) and N stage (N1) were identified as independent risk factors.</p><p><strong>Conclusion: </strong>TICI adjuvant therapy may improve recurrence-free survival, functional recovery, and quality of life in stage III tongue cancer patients.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"18 ","pages":"619697"},"PeriodicalIF":2.6,"publicationDate":"2026-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13390666/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148560697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development and Validation of a Clinical Radiomics Nomogram for Predicting Early Recurrence After Microwave Ablation in Hepatocellular Carcinoma Patients With Type 2 Diabetes.","authors":"Ze Sun, Neng Wang, Xufan Wu, Tianyi Wang, Dong Liu, Yiran Zou, Ruilin He, Ningyang Jia","doi":"10.2147/CMAR.S617875","DOIUrl":"10.2147/CMAR.S617875","url":null,"abstract":"<p><strong>Objective: </strong>To develop and validate a non-invasive model for predicting early recurrence (ER) after microwave ablation (MWA) in patients with hepatocellular carcinoma (HCC) and comorbid type 2 diabetes (T2D).</p><p><strong>Methods: </strong>This retrospective study enrolled 186 HCC patients with T2D who underwent MWA and were divided into training (n=149) and validation (n=37) cohorts. Preoperative clinical parameters and portal-venous phase MRI radiomic features were extracted. A radiomics score (RAD -score) was constructed using the K-nearest neighbors (KNN) algorithm after feature selection. A clinical model was built using logistic regression, and a nomogram integrating clinical factors and the RAD -score was established. Model performance was evaluated using ROC curves, calibration curves, and decision curve analysis (DCA). Kaplan--Meier curves, pathological analysis, and immunohistochemistry validated prognostic stratification.</p><p><strong>Results: </strong>Four core radiomic features were identified. The combined nomogram achieved AUCs of 0.877 (training) and 0.846 (validation), outperforming the clinical (AUC 0.718) and radiomics (AUC 0.774) models alone. In the validation cohort, the sensitivity, specificity, and negative predictive value were 80.0%, 83.8%, and 90.1%, respectively. DCA showed a significant net benefit across threshold probabilities of 0.1-0.9. High-risk patients had a 5.8-fold (training) and 2.51-fold (validation) higher recurrence risk with significantly shorter progression-free survival. Pathological and immunohistochemical analyses confirmed more aggressive tumor features (higher rates of microvascular invasion, poor differentiation, thick-trabecular type, CD34 expression, and glypican-3 expression) in the high-risk group.</p><p><strong>Conclusion: </strong>The nomogram provides a satisfactory prediction of early recurrence within two years after MWA in HCC patients with T2D, enabling individualized postoperative surveillance and intervention.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"18 ","pages":"617875"},"PeriodicalIF":2.6,"publicationDate":"2026-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13387203/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148547582","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}